These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 9708462)

  • 1. Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes.
    Kai H; Ikeda H; Yasukawa H; Kai M; Seki Y; Kuwahara F; Ueno T; Sugi K; Imaizumi T
    J Am Coll Cardiol; 1998 Aug; 32(2):368-72. PubMed ID: 9708462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of levels of serum matrix metalloproteinase-9 in patients with acute myocardial infarction versus unstable angina pectoris versus stable angina pectoris.
    Fukuda D; Shimada K; Tanaka A; Kusuyama T; Yamashita H; Ehara S; Nakamura Y; Kawarabayashi T; Iida H; Yoshiyama M; Yoshikawa J
    Am J Cardiol; 2006 Jan; 97(2):175-80. PubMed ID: 16442358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Gelatinases A and B activities in the serum of patients with various coronary artery disease stages].
    Radenković S; Brajović M; Konjević G; Gopcević K
    Vojnosanit Pregl; 2010 Oct; 67(10):825-30. PubMed ID: 21066874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating matrix metalloproteinase-1 and -3 in patients with an acute coronary syndrome.
    Inoue T; Kato T; Takayanagi K; Uchida T; Yaguchi I; Kamishirado H; Morooka S; Yoshimoto N
    Am J Cardiol; 2003 Dec; 92(12):1461-4. PubMed ID: 14675588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced cardiac production of matrix metalloproteinase-2 and -9 and its attenuation associated with pravastatin treatment in patients with acute myocardial infarction.
    Yasuda S; Miyazaki S; Kinoshita H; Nagaya N; Kanda M; Goto Y; Nonogi H
    Clin Sci (Lond); 2007 Jan; 112(1):43-9. PubMed ID: 16939410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma matrix metalloproteinase-3 level is an independent prognostic factor in stable coronary artery disease.
    Wu TC; Leu HB; Lin WT; Lin CP; Lin SJ; Chen JW
    Eur J Clin Invest; 2005 Sep; 35(9):537-45. PubMed ID: 16128859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevation of ceramide and activation of secretory acid sphingomyelinase in patients with acute coronary syndromes.
    Pan W; Yu J; Shi R; Yan L; Yang T; Li Y; Zhang Z; Yu G; Bai Y; Schuchman EH; He X; Zhang G
    Coron Artery Dis; 2014 May; 25(3):230-5. PubMed ID: 24589572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relation of matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio in peripheral circulating CD14+ monocytes to progression of coronary artery disease.
    Brunner S; Kim JO; Methe H
    Am J Cardiol; 2010 Feb; 105(4):429-34. PubMed ID: 20152234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation analysis of levels of adiponectin and matrix metalloproteinase-9 with stability of coronary heart disease.
    Li Y
    Technol Health Care; 2015; 23 Suppl 1():S95-8. PubMed ID: 26410336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Circulating cytokine measurements by protein chips in patients with acute coronary syndrome].
    Mao H; Liu TZ; Wen M; Chen JJ; Li L; Zhu JK
    Zhonghua Xin Xue Guan Bing Za Zhi; 2008 Mar; 36(3):219-22. PubMed ID: 19099977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relation between upregulation of CD40 system and complex stenosis morphology in patients with acute coronary syndrome.
    Yan JC; Wu ZG; Kong XT; Zong RQ; Zhan LZ
    Acta Pharmacol Sin; 2004 Feb; 25(2):251-6. PubMed ID: 14769218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altered human neutrophil FcγRI and FcγRIII but not FcγRII expression is associated with the acute coronary event in patients with coronary artery disease.
    Zhao N; Mi L; Zhang Y; Li N; Xu J; Xia D; Wang J; Wu Y; Liu X
    Coron Artery Dis; 2017 Jan; 28(1):63-69. PubMed ID: 27604056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ADAMTS4 level in patients with stable coronary artery disease and acute coronary syndromes.
    Zha Y; Chen Y; Xu F; Li T; Zhao C; Cui L
    Biomed Pharmacother; 2010 Mar; 64(3):160-4. PubMed ID: 19944557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pentraxin 3, long expression in mononuclear cells of patients with acute coronary syndrome: Correlation with C-reactive protein and matrix metalloproteinase-9 levels.
    Ma R; Zhang W; Wang T; He X; Huang Z; Zhu J; Yao Z
    J Int Med Res; 2014 Jun; 42(3):677-83. PubMed ID: 24709882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-33, matrix metalloproteinase-9, and tissue inhibitor [corrected] of matrix metalloproteinase-1 in myocardial infarction.
    Guzel S; Serin O; Guzel EC; Buyuk B; Yılmaz G; Güvenen G
    Korean J Intern Med; 2013 Mar; 28(2):165-73. PubMed ID: 23525523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Plasma matrix metalloproteinases-2 and -9 levels are elevated in patients with acute coronary syndrome and coronary chronic total occlusion].
    Tang QD; Wu PS; Hou YQ; Huang Z; Zhou ZJ; Guo ZG; Xiu JC; Wang YG
    Nan Fang Yi Ke Da Xue Xue Bao; 2009 May; 29(5):1004-7. PubMed ID: 19460733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated circulating levels of matrix metalloproteinase-9 and -2 in patients with symptomatic coronary artery disease.
    Zeng B; Prasan A; Fung KC; Solanki V; Bruce D; Freedman SB; Brieger D
    Intern Med J; 2005 Jun; 35(6):331-5. PubMed ID: 15892761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Changes in serum level of carboxy-terminal telopeptide of type I collagen in patients with coronary heart disease].
    Deng Y; Chen LH; Wang XB; Song XD; Ling YN; Chen AH; Yang PZ; Guo JB; Que DD; Chen GM
    Nan Fang Yi Ke Da Xue Xue Bao; 2015 Apr; 35(4):506-10. PubMed ID: 25907933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-inflammatory cytokine profile in acute coronary syndromes: behavior of interleukin-10 in association with serum metalloproteinases and proinflammatory cytokines.
    Tziakas DN; Chalikias GK; Hatzinikolaou HI; Parissis JT; Papadopoulos ED; Trypsianis GA; Papadopoulou E; Tentes IK; Karas SM; Hatseras DI
    Int J Cardiol; 2003 Dec; 92(2-3):169-75. PubMed ID: 14659849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated levels of circulating plasma matrix metalloproteinase 9 in non-small cell lung cancer patients.
    Iizasa T; Fujisawa T; Suzuki M; Motohashi S; Yasufuku K; Yasukawa T; Baba M; Shiba M
    Clin Cancer Res; 1999 Jan; 5(1):149-53. PubMed ID: 9918213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.